



Pfizer Inc.  
235 East 42nd St.  
New York, NY 10017

April 12, 2021

**Subject: TIKOSYN® (dofetilide) 125, 250 and 500 mcg capsules - Supply Shortage Resolved**

Dear Health Care Provider,

The purpose of this letter is to inform you that the supply shortage of TIKOSYN (dofetilide) has been resolved and the following TIKOSYN dosages and presentations are now available for use.

Product	Presentation/ Package	Current Status
TIKOSYN 125 mcg (0.125 mg)	Capsules bottle of 14 (NDC 0069-5800-61) Capsules bottle of 60 (NDC 0069-5800-60) Capsules blister pack of 40 (NDC 0069-5800-43)	Anticipated shortage resolution as of mid April 2021
TIKOSYN 250 mcg (0.25 mg)	Capsules bottle of 14 (NDC 0069-5810-61) Capsules bottle of 60 (NDC 0069-5810-60) Capsules blister pack of 40 (NDC 0069-5810-43)	Anticipated shortage resolution as of mid April 2021
TIKOSYN 500 mcg (0.5 mg)	Capsules bottle of 14 (NDC 0069-5820-61) Capsules bottle of 60 (NDC 0069-5820-60) Capsules blister pack of 40 (NDC 0069-5820-43)	Anticipated shortage resolution as of mid April 2021

Please note the above include Hospital Unit Dose Blister packs and Hospital Distributed 14-count bottles.

The full Prescribing Information, BOXED WARNING, and medication guide for TIKOSYN is available at: <http://labeling.pfizer.com/ShowLabeling.aspx?id=639>.

For additional medical questions on TIKOSYN, please contact Pfizer Medical Information 1-800-438-1985. Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

Sincerely,

Haq Nawaz, MD, MPH, MBA, MS  
US Medical Affairs  
Pfizer Inc.

(c) 2021 Pfizer Inc. All rights reserved.